Keybank National Association OH Lowers Stake in ResMed Inc. (RMD)

Keybank National Association OH reduced its stake in shares of ResMed Inc. (NYSE:RMD) by 12.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 10,976 shares of the medical equipment provider’s stock after selling 1,532 shares during the quarter. Keybank National Association OH’s holdings in ResMed were worth $930,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of the company. Toronto Dominion Bank lifted its stake in shares of ResMed by 12.8% during the second quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock worth $135,000 after buying an additional 197 shares during the period. Pillar Pacific Capital Management LLC lifted its stake in shares of ResMed by 1.2% during the fourth quarter. Pillar Pacific Capital Management LLC now owns 43,755 shares of the medical equipment provider’s stock worth $3,706,000 after buying an additional 540 shares during the period. Mutual of America Capital Management LLC lifted its stake in shares of ResMed by 3.6% during the fourth quarter. Mutual of America Capital Management LLC now owns 16,890 shares of the medical equipment provider’s stock worth $1,430,000 after buying an additional 591 shares during the period. WINTON GROUP Ltd lifted its stake in shares of ResMed by 8.6% during the third quarter. WINTON GROUP Ltd now owns 8,076 shares of the medical equipment provider’s stock worth $622,000 after buying an additional 640 shares during the period. Finally, Advisor Group Inc. lifted its stake in shares of ResMed by 26.7% during the third quarter. Advisor Group Inc. now owns 3,164 shares of the medical equipment provider’s stock worth $244,000 after buying an additional 667 shares during the period. Institutional investors and hedge funds own 60.46% of the company’s stock.

In other ResMed news, insider James Hollingshead sold 600 shares of ResMed stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $84.96, for a total value of $50,976.00. Following the completion of the transaction, the insider now owns 62,602 shares of the company’s stock, valued at $5,318,665.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Pendarvis sold 2,804 shares of ResMed stock in a transaction on Monday, December 4th. The shares were sold at an average price of $84.17, for a total transaction of $236,012.68. Following the completion of the transaction, the insider now directly owns 97,257 shares of the company’s stock, valued at approximately $8,186,121.69. The disclosure for this sale can be found here. Insiders sold 44,783 shares of company stock valued at $4,420,848 in the last ninety days. 1.77% of the stock is owned by corporate insiders.

ResMed Inc. (RMD) opened at $93.78 on Friday. The stock has a market cap of $13,310.00, a price-to-earnings ratio of 32.68 and a beta of 0.92. ResMed Inc. has a 1 year low of $67.04 and a 1 year high of $104.78.

ResMed (NYSE:RMD) last posted its earnings results on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.22. The company had revenue of $601.27 million during the quarter, compared to the consensus estimate of $583.77 million. ResMed had a net margin of 12.98% and a return on equity of 22.75%. The firm’s quarterly revenue was up 13.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.73 earnings per share. research analysts forecast that ResMed Inc. will post 3.34 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 15th. Shareholders of record on Thursday, February 8th will be issued a $0.35 dividend. The ex-dividend date of this dividend is Wednesday, February 7th. This represents a $1.40 dividend on an annualized basis and a yield of 1.49%. ResMed’s payout ratio is 48.78%.

Several equities research analysts have recently commented on RMD shares. Needham & Company LLC reiterated a “sell” rating on shares of ResMed in a research note on Friday, October 27th. Northland Securities restated a “sell” rating and set a $55.00 target price on shares of ResMed in a research report on Friday, October 27th. Barclays boosted their target price on shares of ResMed from $68.00 to $70.00 and gave the company an “underweight” rating in a research report on Friday, October 27th. BMO Capital Markets boosted their target price on shares of ResMed from $70.00 to $74.00 and gave the company a “market perform” rating in a research report on Friday, October 27th. Finally, JPMorgan Chase & Co. boosted their target price on shares of ResMed from $72.00 to $73.00 and gave the company an “overweight” rating in a research report on Monday, October 30th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $74.83.

TRADEMARK VIOLATION WARNING: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/23/keybank-national-association-oh-lowers-stake-in-resmed-inc-rmd.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply